Background Cefmetazole (CMZ) is a carbapenem-sparing option in the treatment of
extended-spectrum beta-lactamase (ESBL)-producing bacterial infection. In this pilot study …

Carbapenems are antimicrobial agents commonly used to treat extended-spectrum β-
lactamase (ESBL)-producing bacteria. Although cefmetazole (CMZ) is considered effective …

Background. We evaluated the activity of meropenem (MER)±RPX7009 (RPX), a serine-β-
lactamase inhibitor (BLI) tested against contemporary isolates of Enterobacteriaceae (ENT) …

Background: We retrospectively investigated whether cefmetazole (CMZ) was equivalently
as effective as meropenem (MEPM) for treating bloodstream infections with extended …

Background High-dose cefepime-tazobactam (WCK 4282) is currently under clinical
development at a dosage of 2 grams/2 grams every 8 hours with prolonged infusion (90 …

Purpose Cefmetazole (CMZ) has received attention as a pharmaceutical intervention for
extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) infections. This …

Objectives To investigate the activities of ceftolozane/tazobactam and imipenem/relebactam
against Escherichia coli, Klebsiella pneumoniae and Pseudomonas aeruginosa isolated …

Background ESBL-producing E. coli (ESBLEC) continues to increase worldwide. For the
infection due to ESBLEC, no antimicrobial agent has clearly demonstrated therapeutic …

Enmetazobactam, formerly AAI101, is a novel penicillanic acid sulfone extended-spectrum β-
lactamase (ESBL) inhibitor. The combination of enmetazobactam with cefepime has entered …

Background Extended-spectrum β-lactamase (ESBL)–producing Enterobacterales have
become a global concern owing to increased infections, high mortality, and limited antibiotic …